[Federal Register Volume 60, Number 42 (Friday, March 3, 1995)]
[Notices]
[Page 11996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-5266]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importation of Controlled Substances; Notice of Application

    Pursuant to Section 1008 of the Controlled Substances Import and 
Export Act (21 U.S.C. 958(i)), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in Schedule I or II and prior to issuing a 
regulation under Section 1002(a) authorizing the importation of such a 
substance, provide manufacturers holding registrations for the bulk 
manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Section 1311.42 of Title 21, Code of 
Federal Regulations (CFR), notice is hereby given that on January 19, 
1995, Abbott Laboratories, IMP, Attn: Plant Manager, U.S. Highway 301 
N., Rocky Mount, North Carolina 27801, made a written request to the 
Drug Enforcement Administration to be registered as an importer of 
Meperidine (9230) a basic class of controlled substance in Schedule II.
    The firm will import the Meperidine to produce vials for a patient 
controlled analgesia pump.
    Any manufacturer holding, or applying for, registration as a bulk 
manufacturer of this basic class of controlled substance may file 
written comments on or objection to the application described above and 
may, at the same time, file a written request for a hearing on such 
application in accordance with 21 CFR 1301.54 in such form as 
prescribed by 21 CFR 1316.47.
    Any such comments, objections, or requests for a hearing may be 
addressed to the Deputy Assistant Administrator, Office of Diversion 
control, Drug Enforcement Administration, United States Department of 
Justice, Washington, DC 20537, Attention: DEA Federal Register 
Representative (CCR), and must be filed no later than (30 days from 
publication).
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1311.42 (b), (c), 
(d), (e), and (f). As noted in a previous notice at 40 FR 43745-46 
(September 23, 1975), all applicants for registration to import a basic 
class of any controlled substance in Schedule I or II are and will 
continue to be required to demonstrate to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, that the requirements for such registration pursuant to 
21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42 (a), (b), (c), 
(d), (e), and (f) are satisfied.

    Dated: February 24, 1995.
Gene R. Haislip,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 95-5266 Filed 3-2-95; 8:45 am]
BILLING CODE 4410-09-M